John L Humm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9214145/publications.pdf

Version: 2024-02-01

159358 95083 4,791 85 30 68 citations g-index h-index papers 90 90 90 6429 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation. Journal of Nuclear Cardiology, 2022, 29, 3179-3188.	1.4	7
2	Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor. Pharmacology Research and Perspectives, 2022, 10, e00898.	1.1	0
3	Optimizing 90Y Particle Density Improves Outcomes After Radioembolization. CardioVascular and Interventional Radiology, 2022, 45, 958-969.	0.9	10
4	SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans. PLoS ONE, 2022, 17, e0266704.	1.1	O
5	Predicting Gemcitabine Delivery by ¹⁸ F-FAC PET in Murine Models of Pancreatic Cancer. Journal of Nuclear Medicine, 2021, 62, 195-200.	2.8	6
6	IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab—pharmacokinetic modeling to optimize therapeutic index. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1166-1177.	3.3	9
7	Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 905-912.	0.4	13
8	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. Journal of the National Cancer Institute, 2021, 113, 742-751.	3.0	98
9	A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast Cancer Research and Treatment, 2021, 188, 415-425.	1.1	7
10	Optimizing reconstruction parameters for quantitative 124I-PET in the presence of therapeutic doses of 131I. EJNMMI Physics, 2021, 8, 50.	1.3	1
11	Application of Community Detection Algorithm to Investigate the Correlation between Imaging Biomarkers of Tumor Metabolism, Hypoxia, Cellularity, and Perfusion for Precision Radiotherapy in Head and Neck Squamous Cell Carcinomas. Cancers, 2021, 13, 3908.	1.7	3
12	Pharmacokinetic Assessment of $\langle \sup 18 \langle \sup F-(2 \langle i \rangle S, \langle i \rangle 4 \langle i \rangle R \langle i \rangle)-4$ -Fluoroglutamine in Patients with Cancer. Journal of Nuclear Medicine, 2020, 61, 357-366.	2.8	23
13	¹¹ C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series. Journal of Nuclear Medicine, 2020, 61, 827-833.	2.8	18
14	18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1446-1457.	3.3	13
15	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. Radiotherapy and Oncology, 2020, 153, 97-105.	0.3	19
16	Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. PLoS ONE, 2020, 15, e0231745.	1.1	7
17	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. Clinical Cancer Research, 2020, 26, 2871-2881.	3.2	69
18	Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴ I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. Journal of Nuclear Medicine, 2019, 60, 1794-1801.	2.8	29

#	Article	IF	CITATIONS
19	lmaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹ Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of Nuclear Medicine, 2019, 60, 1517-1523.	2.8	38
20	Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1221-1227.	2.8	10
21	Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. Journal of Neuro-Oncology, 2019, 143, 101-106.	1.4	17
22	Assessment of SPECT Systems Using Multiple Detector Technologies. , 2019, , .		1
23	¹⁸ F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. Journal of Nuclear Medicine, 2019, 60, 335-341.	2.8	123
24	An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models. International Journal of Radiation Oncology Biology Physics, 2019, 103, 697-708.	0.4	62
25	Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 930-939.	3.3	75
26	Copper-64 trastuzumab PET imaging: a reproducibility study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 191-198.	0.4	21
27	¹¹ C-Choline Pharmacokinetics in Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1672-1678.	2.8	11
28	Reproducibility and Repeatability of Semiquantitative ¹⁸ F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. Journal of Nuclear Medicine, 2018, 59, 1516-1523.	2.8	20
29	Inter-operator variability in compartmental kinetic analysis of 18 F-fluoromisonidazole dynamic PET. Clinical Imaging, 2018, 49, 121-127.	0.8	2
30	Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features. Radiotherapy and Oncology, 2018, 127, 36-42.	0.3	55
31	Technical Note: Scintillation well counters and particle counting digital autoradiography devices can be used to detect activities associated with genomic profiling adequacy of biopsy specimens obtained after a low activity ¹⁸ Fâ€ <scp>FDG</scp> injection. Medical Physics, 2018, 45, 2179-2185.	1.6	8
32	PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine, 2018, 59, 1225-1233.	2.8	51
33	A phase II study of radioimmunotherapy with intraventricular ¹³¹ lâ€3F8 for medulloblastoma. Pediatric Blood and Cancer, 2018, 65, e26754.	0.8	46
34	Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 217.	3.4	93
35	18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model. EJNMMI Research, 2018, 8, 53.	1.1	5
36	TMSOTf assisted synthesis of 2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine ([18F]FAC). PLoS ON 2018, 13, e0196784.	NE, _{1.1}	3

#	Article	IF	CITATIONS
37	Multiparametric Imaging of Tumor Hypoxia and Perfusion with sup 18 / sup F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. Journal of Nuclear Medicine, 2017, 58, 1072-1080.	2.8	31
38	Pharmacokinetic Analysis of Dynamic ¹⁸ F-Fluoromisonidazole PET Data in Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 911-919.	2.8	22
39	Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nature Communications, 2017, 8, 14292.	5.8	90
40	Relaxed ordered subset preconditioned alternating projection algorithm for PET reconstruction with automated penalty weight selection. Medical Physics, 2017, 44, 4083-4097.	1.6	10
41	In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2′-deoxy-2′-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models. Molecular Imaging and Biology, 2017, 19, 885-892.	1.3	14
42	A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. Translational Oncology, 2017, 10, 760-765.	1.7	33
43	Evaluation of the tumor registration error in biopsy procedures performed under realâ€time PET/CT guidance. Medical Physics, 2017, 44, 5089-5095.	1.6	5
44	Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1682-1691.	3.3	33
45	Initial performance studies of a wearable brain positron emission tomography camera based on autonomous thin-film digital Geiger avalanche photodiode arrays. Journal of Medical Imaging, 2016, 4, 011003.	0.8	7
46	Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. EJNMMI Research, 2016, 6, 79.	1.1	25
47	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus–Related Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 9-17.	0.4	121
48	Adaptation, Commissioning, and Evaluation of a 3D Treatment Planning System for High-Resolution Small-Animal Irradiation. Technology in Cancer Research and Treatment, 2016, 15, 460-471.	0.8	6
49	¹⁸ F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation. Journal of Nuclear Medicine, 2016, 57, 1052-1057.	2.8	50
50	Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. Journal of Nuclear Medicine, 2016, 57, 334-341.	2.8	16
51	PETSTEP: Generation of synthetic PET lesions for fast evaluation of segmentation methods. Physica Medica, 2015, 31, 969-980.	0.4	28
52	Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 299-304.	0.7	6
53	Guest Editorial. Seminars in Nuclear Medicine, 2015, 45, 98-100.	2.5	1
54	Radium-223 in the Treatment of Osteoblastic Metastases: A Critical Clinical Review. International Journal of Radiation Oncology Biology Physics, 2015, 91, 898-906.	0.4	49

#	Article	IF	Citations
55	Feasibility of In Situ, High-Resolution Correlation of Tracer Uptake with Histopathology by Quantitative Autoradiography of Biopsy Specimens Obtained Under ¹⁸ F-FDG PET/CT Guidance. Journal of Nuclear Medicine, 2015, 56, 538-544.	2.8	28
56	PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1700-1706.	3.3	13
57	Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models. International Journal of Radiation Oncology Biology Physics, 2015, 93, 444-453.	0.4	12
58	Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Science Translational Medicine, 2014, 6, 260ra149.	5.8	589
59	Assessing and accounting for the impact of respiratory motion on FDG uptake and viable volume for liver lesions in freeâ€breathing PET using respirationâ€suspended PET images as reference. Medical Physics, 2014, 41, 091905.	1.6	17
60	PET quantification with a histogram derived total activity metric: Superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. Nuclear Medicine and Biology, 2014, 41, 410-418.	0.3	33
61	The potential of theragnostic 124I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma. Neuro-Oncology, 2014, 16, 800-806.	0.6	38
62	David E. Charlton (1936–2013). Radiation Research, 2013, 180, 553-555.	0.7	2
63	Image-Guided Po ₂ Probe Measurements Correlated with Parametric Images Derived from ¹⁸ F-Fluoromisonidazole Small-Animal PET Data in Rats. Journal of Nuclear Medicine, 2012, 53, 1608-1615.	2.8	34
64	Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) Pharmacokinetics in FaDu Xenograft Tumors and Correlation With Microscopic Markers of Hypoxia. International Journal of Radiation Oncology Biology Physics, 2012, 84, e393-e399.	0.4	32
65	Introduction to the Special Issue on Molecular Imaging in Radiation Biology. Radiation Research, 2012, 177, 329-330.	0.7	2
66	Measured dose rate constant from oncology patients administered 18F for positron emission tomography. Medical Physics, 2012, 39, 6071-6079.	1.6	13
67	Imaging in Radiation Oncology * *This chapter is an update and expansion of material presented in the first edition by C.C. Ling, R. Mohan, L.E. Reinstein, and L.N. Rothenberg, and in the second edition by the current authors , 2010, , 120-154.		1
68	In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression. Nuclear Medicine and Biology, 2009, 36, 821-831.	0.3	15
69	Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 39-46.	3.3	29
70	The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by 111Indium-labeled humanized monoclonal antibody 3S193. European Journal of Radiology, 2008, 67, 292-299.	1.2	6
71	Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 1311 by use of 1241 PET and 3-dimensional internal dosimetry software. Journal of Nuclear Medicine, 2007, 48, 143-9.	2.8	59
72	Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1493-1502.	0.4	183

#	Article	lF	CITATIONS
73	Dependence of FDG uptake on tumor microenvironment. International Journal of Radiation Oncology Biology Physics, 2005, 62, 545-553.	0.4	170
74	lodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 117-128.	3. 3	88
75	From PET detectors to PET scanners. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1574-1597.	3.3	186
76	Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. International Journal of Radiation Oncology Biology Physics, 2000, 47, 551-560.	0.4	885
77	Use of PET to monitor the response of lung cancer to radiation treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 861-866.	3.3	108
78	An automated iterative algorithm for water and fat decomposition in three-point Dixon magnetic resonance imaging. Medical Physics, 1999, 26, 2341-2347.	1.6	9
79	Changes in FDG Tumor Uptake during and after Fractionated Radiation Therapy in a Rodent Tumor Xenograft. Molecular Imaging and Biology, 1999, 2, 289-296.	0.3	8
80	Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer, 1997, 80, 2505-2509.	2.0	377
81	Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer, 1997, 80, 2505-9.	2.0	174
82	Electron dose profile shaping by modulation of a scanning elementary beam. Medical Physics, 1996, 23, 33-44.	1.6	22
83	Dosimetric properties of a scanned beam microtron at low monitor unit settings: Importance for conformal therapy. Medical Physics, 1996, 23, 329-335.	1.6	8
84	General solution of the radioactive parent-daughter relationship. Medical Physics, 1994, 21, 1739-1740.	1.6	1
85	Dosimetry of Auger-electron-emitting radionuclides: Report No. 3 of AAPM Nuclear Medicine Task Group No. 6. Medical Physics, 1994, 21, 1901-1915.	1.6	128